X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (69986) 69986
Book Review (20700) 20700
Publication (8122) 8122
Book Chapter (504) 504
Book / eBook (349) 349
Newspaper Article (295) 295
Newsletter (241) 241
Conference Proceeding (195) 195
Dissertation (71) 71
Transcript (24) 24
Magazine Article (14) 14
Reference (13) 13
Data Set (12) 12
Trade Publication Article (7) 7
Web Resource (6) 6
Paper (3) 3
Government Document (2) 2
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (59934) 59934
humans (42776) 42776
animals (30738) 30738
male (18188) 18188
proteins (15495) 15495
female (15330) 15330
oncology (13590) 13590
mice (12979) 12979
cancer (12492) 12492
apoptosis (10922) 10922
kinases (9197) 9197
pharmacology & pharmacy (9190) 9190
research (8992) 8992
cell biology (8634) 8634
analysis (8484) 8484
signal transduction (8304) 8304
biochemistry & molecular biology (8164) 8164
middle aged (8144) 8144
gene expression (8003) 8003
expression (7780) 7780
rats (7543) 7543
health aspects (7260) 7260
aged (6745) 6745
care and treatment (6726) 6726
oxidative stress (6504) 6504
phosphorylation (6438) 6438
article (6400) 6400
adult (6380) 6380
physiological aspects (6332) 6332
inflammation (6330) 6330
rodents (6012) 6012
activation (5874) 5874
medicine (5321) 5321
research article (5239) 5239
signal transduction - drug effects (5128) 5128
cell line, tumor (4925) 4925
protein kinase inhibitors - therapeutic use (4907) 4907
mutation (4849) 4849
genetic aspects (4825) 4825
multidisciplinary sciences (4807) 4807
antineoplastic agents - therapeutic use (4800) 4800
chemotherapy (4695) 4695
tumors (4692) 4692
cells (4552) 4552
treatment outcome (4430) 4430
neurosciences (4289) 4289
apoptosis - drug effects (4123) 4123
disease models, animal (4094) 4094
cells, cultured (4062) 4062
gene-expression (3952) 3952
inhibition (3952) 3952
medicine, research & experimental (3902) 3902
science (3820) 3820
physiology (3775) 3775
risk factors (3773) 3773
in-vitro (3740) 3740
studies (3724) 3724
medicine & public health (3709) 3709
development and progression (3707) 3707
biology (3686) 3686
protein kinase inhibitors - adverse effects (3613) 3613
metastasis (3580) 3580
hematology (3555) 3555
immunology (3537) 3537
review (3526) 3526
drug therapy (3480) 3480
metabolism (3456) 3456
mice, inbred c57bl (3405) 3405
abridged index medicus (3353) 3353
medical research (3250) 3250
genes (3243) 3243
therapy (3210) 3210
nf-kappa-b (3161) 3161
prognosis (3156) 3156
in-vivo (3138) 3138
dose-response relationship, drug (3135) 3135
toxicology (3119) 3119
cell line (3103) 3103
antineoplastic agents - pharmacology (3087) 3087
endocrinology & metabolism (3065) 3065
cytokines (3039) 3039
cell cycle (3010) 3010
antineoplastic agents - adverse effects (3006) 3006
rats, sprague-dawley (2994) 2994
enzymes (2991) 2991
protein (2965) 2965
cancer therapies (2876) 2876
clinical trials (2802) 2802
patients (2715) 2715
diabetes (2704) 2704
aged, 80 and over (2696) 2696
cell proliferation (2692) 2692
time factors (2687) 2687
cell proliferation - drug effects (2651) 2651
survival (2651) 2651
protein kinases (2643) 2643
biochemistry (2613) 2613
breast cancer (2606) 2606
protein kinase inhibitors - pharmacology (2594) 2594
toxicity (2587) 2587
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (230) 230
UofT at Mississauga - Stacks (27) 27
Collection Dvlpm't (Acquisitions) - Vendor file (24) 24
UTL at Downsview - May be requested (18) 18
Collection Dvlpm't (Acquisitions) - Closed Orders (15) 15
Online Resources - Online (13) 13
UofT at Scarborough - Stacks (13) 13
Engineering & Comp. Sci. - Stacks (12) 12
Chemistry (A D Allen) - Stacks (10) 10
Earth Sciences (Noranda) - Stacks (7) 7
UofT at Scarborough - Withdrawn (4) 4
Gerstein Science - Circulation Desk (2) 2
Physics - Stacks (2) 2
St. Michael's College (John M. Kelly) - 2nd Floor (2) 2
UofT at Mississauga - Reference (2) 2
Chemistry (A D Allen) - May be requested in 6-10 wks (1) 1
Collection Dvlpm't (Acquisitions) - Cancelled Order (1) 1
Engineering & Comp. Sci. - Reference (1) 1
Gerstein Science - Reference (1) 1
Trinity College (John W Graham) - Oversize (1) 1
UofT at Mississauga - Missing (1) 1
UofT at Scarborough - May be requested in 6-10 wks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (70765) 70765
French (100) 100
German (96) 96
Japanese (83) 83
Spanish (67) 67
Chinese (66) 66
Russian (12) 12
Czech (10) 10
Hungarian (7) 7
Polish (7) 7
Dutch (6) 6
Swedish (6) 6
Danish (4) 4
Italian (4) 4
Norwegian (3) 3
Turkish (3) 3
Finnish (2) 2
Portuguese (2) 2
Croatian (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 9, pp. 829 - 838
Alectinib, a potent ALK tyrosine kinase inhibitor, was more effective and somewhat less toxic than crizotinib when used as primary therapy in patients with ALK... 
RESISTANT | MEDICINE, GENERAL & INTERNAL | MODELS | ANTITUMOR-ACTIVITY | INHIBITOR ALECTINIB | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2015, Volume 372, Issue 18, pp. 1689 - 1699
AZD9291, an irreversible inhibitor of epidermal growth factor receptor, was associated with tumor responses in the majority of patients with advanced... 
MEDICINE, GENERAL & INTERNAL | GEFITINIB | PLACEBO | PHASE-III | ACQUIRED-RESISTANCE | OPEN-LABEL | MUTATIONS | AFATINIB | IRREVERSIBLE EGFR | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Acrylamides - pharmacokinetics | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Aniline Compounds - administration & dosage | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Non-Small-Cell Lung - genetics | Aniline Compounds - pharmacokinetics | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Acrylamides - administration & dosage | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Aniline Compounds - adverse effects | Acrylamides - adverse effects | Clinical trials | Care and treatment | Usage | Diagnosis | Lung cancer, Non-small cell | Patient outcomes | Tyrosine | Appetite | Inhibitor drugs | Epidermal growth factor receptors | Lung | Lung cancer | Diarrhea | Nausea | Drug resistance | Kinases | Patients | Epidermal growth factor | Pharmacokinetics | Protein-tyrosine kinase | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2012, Volume 367, Issue 2, pp. 107 - 114
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2015, Volume 373, Issue 3, pp. 209 - 219
In women with hormone-receptor–positive metastatic breast cancer that had progressed after endocrine therapy, palbociclib plus fulvestrant was associated with... 
TARGET | MEDICINE, GENERAL & INTERNAL | THERAPY | FULVESTRANT | CLINICAL-TRIALS | CYCLIN D | RESISTANCE | MUTATIONS | COMBINATION | ESTROGEN-RECEPTOR | 4/6 INHIBITOR PALBOCICLIB | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Estradiol - analogs & derivatives | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptors, Estrogen - analysis | Protein Kinase Inhibitors - adverse effects | Receptors, Progesterone - analysis | Pyridines - adverse effects | Aged, 80 and over | Estradiol - adverse effects | Adult | Female | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Pyridines - therapeutic use | Double-Blind Method | Estradiol - therapeutic use | Biomarkers - analysis | Piperazines - therapeutic use | Breast Neoplasms - drug therapy | Piperazines - adverse effects | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Aged | Receptor, ErbB-2 - analysis | Women | Hormone receptors | Care and treatment | Usage | Breast cancer | Diagnosis | Health aspects | Thrombocytopenia | Leukopenia | Endocrine therapy | Fatigue | Metastasis | Cancer therapies | Cyclin-dependent kinase 4 | Fulvestrant | Metastases | Epidermal growth factor | Womens health | S phase | Cell cycle | Neutropenia | G1 phase | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 22, pp. 2071 - 2082
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2015, Volume 372, Issue 1, pp. 30 - 39
In patients with melanomas containing activating BRAF mutations, the combination of a BRAF inhibitor and a MEK inhibitor improved overall survival, as compared... 
CRITERIA | BRAF-MUTATED MELANOMA | METASTATIC MELANOMA | RAF INHIBITION | MEDICINE, GENERAL & INTERNAL | MEK INHIBITION | ACQUIRED-RESISTANCE | V600E MUTATION | TUMORS | OVERCOME | VEMURAFENIB | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Male | Protein Kinase Inhibitors - adverse effects | Young Adult | Pyridones - administration & dosage | Aged, 80 and over | Adult | Female | Skin Neoplasms - pathology | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Kaplan-Meier Estimate | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Indoles - adverse effects | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Adolescent | Intention to Treat Analysis | Survival Analysis | Sulfonamides - adverse effects | Indoles - therapeutic use | Aged | Pyrimidinones - administration & dosage | Mutation | Pyridones - adverse effects | Melanoma - mortality | Patients | Health aspects | Risk factors | Melanoma | Toxicity | Medical treatment | MEK inhibitors | Antitumor activity | Metastasis | Kinases | Cancer therapies | Clinical outcomes | Metastases | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 20, pp. 1925 - 1936
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 390, Issue 10089, pp. 29 - 39